dehydroepiandrosterone and Coronary Artery Disease studies

Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.

Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.

Research Excerpts

Excerpt	Relevance	Reference
" Observational studies do not support the hypothesis that dehydroepiandrosterone sulfate deficiency is a risk factor for coronary artery disease."	4.82	Androgens and coronary artery disease. ( von Eckardstein, A; Wu, FC, 2003)
" The aim of the study was to analyze the levels of gonadal hormones (estradiol, progesterone, follicle-stimulating hormone, luteinizing hormone, testosterone and dehydroepiandrosterone) measured in the luteal phase, in 65 normally menstruating women post myocardial infarction (MI) and to investigate a possible relationship between the hormone profile and selected coronary artery disease (CAD) risk factors."	3.77	A levels of endogenous gonadal hormones and their relationship with selected coronary artery disease risk factors among young women post myocardial infarction. ( Ablewska, U; Hryniewiecki, T; Jankowski, K; Liszewska-Pfejfer, D; Rzewuska, E, 2011)
"Serum levels of DHEA sulfate are inversely associated with cardiovascular death in men, and urinary dehydroepiandrosterone (DHEA) levels are inversely associated with clinical manifestations of coronary artery disease."	3.68	Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. ( Achuff, SC; Gordon, GB; Herrington, DM; Kwiterovich, PO; Pearson, TA; Trejo, JF; Weisman, HF, 1990)
"Accelerated coronary atherosclerosis has become a critical problem in cardiac transplantation."	1.29	Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. ( Dworkin, GH; Eich, DM; Hess, ML; Johnson, DE; Ko, D; Nestler, JE; Wechsler, AS, 1993)

Research

Studies (15)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Endothelial Progenitor Cells

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (33.33)	18.2507
2000's	8 (53.33)	29.6817
2010's	1 (6.67)	24.3611
2020's	1 (6.67)	2.80

Authors	Studies
Ohlsson, C	1
Nethander, M	1
Norlén, AK	1
Poutanen, M	1
Gudmundsson, EF	1
Aspelund, T	1
Sigurdsson, S	1
Ryberg, H	1
Gudnason, V	1
Tivesten, Å	1
Ouyang, P	1
Vaidya, D	1
Dobs, A	1
Golden, SH	1
Szklo, M	1
Heckbert, SR	1
Kopp, P	1
Gapstur, SM	1
Srinivasan, M	1
Irving, BA	1
Dhatariya, K	1
Klaus, KA	1
Hartman, SJ	1
McConnell, JP	1
Nair, KS	1
Ablewska, U	1
Jankowski, K	1
Rzewuska, E	1
Liszewska-Pfejfer, D	1
Hryniewiecki, T	1
Wu, FC	1
von Eckardstein, A	1
Dobrzycki, S	1
Zukowska-Serwatka, K	1
Ładny, JR	1
Wranicz, JK	1
Rosiak, M	1
Cygankiewicz, I	1
Kula, K	1
Maggio, M	1
Ceda, GP	1
De Cicco, G	1
Cattadori, E	1
Visioli, S	1
Ablondi, F	1
Beghi, C	1
Gherli, T	1
Basaria, S	1
Ceresini, G	1
Valenti, G	1
Ferrucci, L	1
Eich, DM	1
Nestler, JE	1
Johnson, DE	1
Dworkin, GH	1
Ko, D	1
Wechsler, AS	1
Hess, ML	1
Herrington, DM	2
Barud, W	1
Palusiński, R	1
Hanzlik, J	1
LaCroix, AZ	1
Yano, K	1
Reed, DM	1
Hauner, H	1
Stangl, K	1
Burger, K	1
Busch, U	1
Blömer, H	1
Pfeiffer, EF	1
Gordon, GB	1
Achuff, SC	1
Trejo, JF	1
Weisman, HF	1
Kwiterovich, PO	1
Pearson, TA	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men Title Changed With New Protocol (12/14/09): Hormonal Regulation of HDL-C in Men[NCT00729859]	Phase 2	31 participants (Actual)	Interventional	2008-12-31	Completed
The Effect of Dihydrotestosterone (DHT) on Prostate Tissue Androgen Concentrations and Inflammation in Normal Men[NCT00490022]	Phase 1/Phase 2	31 participants (Actual)	Interventional	2007-06-30	Completed
[NCT00005168]		0 participants	Observational	1984-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Number of CD33 + CD134+ cells as a percentage of all lymphocytes (NCT00729859)
Timeframe: Baseline, Day 28

Estradiol Concentration

Fasting Lipid Levels

Fasting Serum Insulin

Follicle Stimulating Hormone (FSH)

Homeostasis Model of Insulin Resistance (HOMA-IR)

Intervention	percentage of all lymphocytes (Mean)
	Baseline	Day 28
Group 1: Acyline + Placebo Gel + Placebo Pill	0.101	0.081

Intervention	pmol/L (Mean)
	Baseline	Day 28
Group 1: Acyline + Placebo Gel, Placebo Pill	95.4	31.9
Group 2: Acyline, Testosterone Gel	117.8	109.0
Group 3: Acyline, Testosterone Gel, Anastrozole Pill	96.3	36.5

Intervention	mmol/L (Mean)
	Total cholesterol Day 0	Total cholesterol Day 28	Total cholesterol Day 56	LDL choesterol Day 0	LDL cholesterol Day 28	LDL cholesterol Day 56	HDL cholesterol Day 0	HDL cholesterol Day 28	HDL cholesterol Day 56	Triglycerides Day 0	Triglycerides Day 28	Triglycerides Day 56
Group 1: Acyline + Placebo Gel, Placebo Pill	4.97	5.44	4.95	2.95	3.29	2.87	1.19	1.37	1.19	1.79	1.73	1.89
Group 2: Acyline, Testosterone Gel, Placebo Pill	4.48	4.51	4.14	2.77	2.80	2.49	1.32	1.32	1.32	0.82	0.86	0.80
Group 3: Acyline, Testosterone Gel, Oral Anastrozole	4.56	4.56	4.27	2.67	2.75	2.51	1.40	1.32	1.30	1.08	1.08	1.02

Intervention	picomolar (Mean)
	Baseline	Day 28	Day 56
Group 1: Acyline + Placebo Gel, Placebo Pill	54	69	54
Group 2: Acyline, Testosterone Gel, Placebo Pill	65	59	64
Group 3: Acyline, Testosterone Gel, Oral Anastrozole	50	42	50

Intervention	IU/L (Mean)
	Baseline	Day 28
Group 1: Acyline + Placebo Gel, Placebo Pill	4.2	0.42
Group 2: Acyline, Testosterone Gel	2.9	0.39
Group 3: Acyline, Testosterone Gel, Anastrazole Pill	2.5	0.87

HOMA IR is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher HOMA IR numbers are associated with increased insulin resistance and decreased insulin sensitivity. (NCT00729859)
Timeframe: Baseline, Day 28, Day 56

Luteinizing Hormone Concentration (LH)

Quantitative Insulin Sensitivity Check Index (QUICKI)

Intervention	HOMA score (Mean)
	Baseline	Day 28	Day 56
Group 1: Acyline + Placebo Gel, Placebo Pill	1.8	2.4	2.2
Group 2: Acyline, Testosterone Gel, Placebo Pill	2.0	1.9	1.9
Group 3: Acyline, Testosterone Gel, Oral Anastrozole	1.6	1.4	1.7

Intervention	IU/L (Mean)
	Baseline	Day 28
Group 1: Acyline + Placebo Gel, Placebo Pill	4.3	0.31
Group 2: Acyline, Testosterone Gel	4.7	0.69
Group 3: Acyline, Testosterone Gel, Anastrozole	4.4	1.55

QUICKI is a measure of insulin sensitivity calculated using fasting insulin and glucose concentration in a participants blood. Higher QUICKI are associated with decreased insulin resistance and increased insulin sensitivity. (NCT00729859)
Timeframe: Baseline, Day 28, Day 56

Sex Hormone Binding Globulin (SHBG)

Testosterone Concentration

Prostate Epithelial Cell Proliferation

Intervention	QUICKI index (Mean)
	Baseline	Day 28	Day 56
Group 1: Acyline + Placebo Gel, Placebo Pill	0.36	0.34	0.35
Group 2: Acyline, Testosterone Gel, Placebo Pill	0.35	0.35	0.35
Group 3: Acyline, Testosterone Gel, Oral Anastrozole	0.36	0.38	0.36

Intervention	nmol/L (Mean)
	Baseline	Day 28
Group 1: Acyline + Placebo Gel, Placebo Pill	34.9	37.5
Group 2: Acyline, Testosterone Gel	23.0	22.1
Group 3: Acyline, Testosterone Gel, Anastrozole Pill	27.6	25.1

Intervention	nmol/L (Mean)
	Baseline testosterone concentration	Day 28 testosterone concentration
Group 1: Acyline + Placebo Gel, Placebo Pill	15.4	0.8
Group 2: Acyline, Testosterone Gel	16.3	17.8
Group 3: Acyline, Testosterone Gel, Anastrozole	16.5	19.0

Prostate epithelial cell proliferation in the prostate biopsy tissue was measured using Ki-67 immunohistochemical staining of prostate epithelium as a marker of cell proliferation (values are number of Ki-67 positive stained cells per 100 prostate epithelial cells). The placebo and treatment groups were compared. (NCT00490022)
Timeframe: 28-days

Prostate Tissue DHT and Testosterone Levels After 28 Days of Treatment With Dihydrotestosterone [DHT] Gel Versus Placebo Gel.

Intervention	#pos.Ki-67cells per100 prst. epth cells (Mean)
Placebo DHT Gel	1.3
DHT Gel	0.7

After 4 weeks of either daily dihydrotestosterone transdermal gel or placebo gel, subjects underwent a prostate biopsy. Intraprostatic hormone concentrations, specifically DHT and Testosterone, were measured. Unit of measure is ng/g. (NCT00490022)
Timeframe: 28-days

Reviews

Trials

Other Studies

11 other studies available for dehydroepiandrosterone and Coronary Artery Disease

Article	Year
Androgens and coronary artery disease. Endocrine reviews, 2003, Volume: 24, Issue:2 Topics: Adult; Animals; Cardiovascular Physiological Phenomena; Cardiovascular System; Cholesterol, HDL; Cor	2003
Androgens and coronary artery disease. Endocrine reviews, 2003, Volume: 24, Issue:2 Topics: Adult; Animals; Cardiovascular Physiological Phenomena; Cardiovascular System; Cholesterol, HDL; Cor	2003
Androgens and coronary artery disease. Endocrine reviews, 2003, Volume: 24, Issue:2 Topics: Adult; Animals; Cardiovascular Physiological Phenomena; Cardiovascular System; Cholesterol, HDL; Cor	2003
Androgens and coronary artery disease. Endocrine reviews, 2003, Volume: 24, Issue:2 Topics: Adult; Animals; Cardiovascular Physiological Phenomena; Cardiovascular System; Cholesterol, HDL; Cor	2003
[Pathogenetic basis of androgen administration in cardiology]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2003, Volume: 14, Issue:81 Topics: Coronary Artery Disease; Dehydroepiandrosterone; Female; Humans; Male; Risk Factors	2003
[Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulphate (DHEAS) in men with coronary artery disease]. Polskie Archiwum Medycyny Wewnetrznej, 2004, Volume: 111, Issue:6 Topics: Age Factors; Aging; Animals; Coronary Artery Disease; Dehydroepiandrosterone; Dehydroepiandrosterone	2004

Article	Year
Serum DHEA and Testosterone Levels Associate Inversely With Coronary Artery Calcification in Elderly Men. The Journal of clinical endocrinology and metabolism, 2023, Nov-17, Volume: 108, Issue:12 Topics: Aged; Androstenedione; Coronary Artery Disease; Dehydroepiandrosterone; Dihydrotestosterone; Estradi	2023
Sex hormone levels and subclinical atherosclerosis in postmenopausal women: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2009, Volume: 204, Issue:1 Topics: Aged; Aged, 80 and over; Calcinosis; Carotid Artery Diseases; Coronary Artery Disease; Cross-Section	2009
A levels of endogenous gonadal hormones and their relationship with selected coronary artery disease risk factors among young women post myocardial infarction. Acta biochimica Polonica, 2011, Volume: 58, Issue:3 Topics: Adult; Coronary Artery Disease; Dehydroepiandrosterone; Estradiol; Female; Follicle Stimulating Horm	2011
Acute changes in circulating hormones in older patients with impaired ventricular function undergoing on-pump coronary artery bypass grafting. Journal of endocrinological investigation, 2005, Volume: 28, Issue:8 Topics: Aged; Aged, 80 and over; Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Artery Disease; De	2005
DHEA and health: more questions than answers. Harvard men's health watch, 2007, Volume: 11, Issue:9 Topics: Aging; Cognition; Coronary Artery Disease; Dehydroepiandrosterone; Depression; Dietary Supplements;	2007
Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation, 1993, Volume: 87, Issue:1 Topics: Animals; Coronary Artery Disease; Dehydroepiandrosterone; Heart Transplantation; Hypercholesterolemi	1993
Dehydroepiandrosterone and coronary atherosclerosis. Annals of the New York Academy of Sciences, 1995, Dec-29, Volume: 774 Topics: Adult; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Dehydr	1995
[Influence of androgens on cardiovascular system in men]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2001, Volume: 54, Issue:5-6 Topics: Androgens; Coronary Artery Disease; Dehydroepiandrosterone; Humans; Male	2001
Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation, 1992, Volume: 86, Issue:5 Topics: Age Factors; Aged; Case-Control Studies; Coronary Artery Disease; Coronary Vessels; Dehydroepiandros	1992
Sex hormone concentrations in men with angiographically assessed coronary artery disease--relationship to obesity and body fat distribution. Klinische Wochenschrift, 1991, Sep-16, Volume: 69, Issue:14 Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Body Mass Index; Coronary Angiography; Coronary Artery	1991
Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. Journal of the American College of Cardiology, 1990, Volume: 16, Issue:6 Topics: Adult; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Dehydroepiandrosterone; Dehy	1990

Intervention	ng/g (Mean)
	DHT concentrations	Testosterone Concentrations
DHT Gel	3.1	0.4
Placebo DHT Gel	2.8	0.6